{"filings":[{"id":748878,"accession_number":"0001493152-26-026431","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-05-29T21:10:15+00:00","items":["5.07"],"status":"ready","headline":"Immix Biopharma shareholders elect directors and ratify Crowe LLP as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees (including Ilya Rachman, Gabriel Morris, Jason Hsu) elected with over 35M votes each; broker non-votes ~6.4M.","Ratification of Crowe LLP as independent auditor for FY 2026 passed: 42.3M For, 11.5K Against, 18.4K Abstentions.","Meeting held May 22, 2026; results reported on May 29, 2026; overwhelming support for all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584517,"accession_number":"0001493152-26-024872","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-05-21T21:28:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma prices $150M public offering of 16.8M shares at $8.94","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.","Offering of 16,778,524 shares priced at $8.94 per share; closes May 22, 2026.","Net proceeds to fund NXC-201 development, working capital, and general corporate purposes.","Cash runway extended to mid-2028 with existing cash plus offering net proceeds.","Morgan Stanley leads underwriters; BofA Securities, LifeSci Capital, Mizuho, Needham co-manage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563116,"accession_number":"0001493152-26-024707","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-05-21T10:04:26+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).","CR rate now 95% (19 of 20 patients) in Phase 2 NEXICART-2; no relapses observed in patients reaching CR.","All CRs reached within one year of follow-up post-dosing; median time to initial response was 7 days.","Phase 3 trial in newly diagnosed AL Amyloidosis planned to start in first half of 2027.","Next NEXICART-2 data update expected late September 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110364,"accession_number":"0001493152-26-013663","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.","Topline results expected Q3 2026, followed by BLA submission and planned commercial launch for NXC-201.","Onboarded Chief Medical Officer Richard Graydon, MD, PhD, formerly of Merck and Johnson & Johnson.","NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations; market for AL Amyloidosis estimated at $6B in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110363,"accession_number":"0001493152-26-012721","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma ups ATM offering to $100M from $50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased max aggregate offering price under ATM agreement from $50M to $100M.","Amendment updates registration statement to Form S-3 (File 333-292665).","Sales agent commission remains 3% of gross proceeds; $50K expense cap.","Company may sell shares at market prices from time to time; no minimum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126961,"accession_number":"0001493152-25-026697","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.","Net proceeds expected ~$93.7M after underwriting discounts and estimated expenses.","Underwriting agreement with Morgan Stanley & Co. LLC as representative of underwriters.","Offering expected to close December 9, 2025, subject to customary closing conditions.","Pre-funded warrants exercisable immediately at $0.01/share, with 4.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126960,"accession_number":"0001493152-25-026500","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.","MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.","Organ responses observed in 70% of evaluable patients; no neurotoxicity and only low-grade CRS (median 1 day).","NEXICART-2 final readout and BLA submission planned for 2026; therapy has FDA RMAT and orphan designations.","Current standard-of-care CR rate in this setting is under 10%, highlighting high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126959,"accession_number":"0001493152-25-025182","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma files updated auditor consents for S-3 registration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed updated consents from former auditor KMJ Corbin and current auditor Crowe LLP, dated Nov 26, 2025.","Consents relate to audit reports on FY2024 financials included in Form 10-K filed Mar 25, 2025.","Consents are for incorporation into Registration Statement on Form S-3 (No. 333-290725)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143759,"accession_number":"0001493152-25-012804","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.","Gross proceeds ~$9.1M for working capital and general corporate purposes; closed on Sept 5, 2025.","Warrants are non-transferable, exercisable for 10 years, and only for cash.","Nancy Chang, Ph.D. appointed to board effective Sept 8, 2025; co-founded Tanox (XOLAIR developer).","Resale registration statement to be filed with SEC within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161993,"accession_number":"0001641172-25-016120","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immix Biopharma stockholders elect 8 directors and ratify Crowe LLP as 2025 auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected with 'for' votes ranging from 13.4M to 14.6M; broker non-votes 5.5M across all director proposals.","Ratification of Crowe LLP as independent auditor approved with 19.9M for, 47.6K against, 98.4K abstentions (no broker non-votes).","72.1% of outstanding shares (20.1M) were present or represented at the June 20, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161992,"accession_number":"0001641172-25-013417","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immix Biopharma enters ATM equity offering with Citizens JMP Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows at-the-market sales of common stock; 3% commission to Agent.","Sales conducted under existing S-3 shelf (File No. 333-269100), filed January 2023.","No immediate sale; company controls timing, price, and size of any offerings.","Agent indemnified and reimbursed up to $50,000 for specified expenses.","Shares subject to registration limits and Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213143,"accession_number":"0001493152-24-029174","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.","NEXICART-2 U.S. Phase 1b/2 trial to evaluate NXC-201; builds on prior ex-U.S. data showing 92% overall response rate.","NXC-201 is the only CAR-T therapy in development for AL Amyloidosis and has Orphan Drug Designation from FDA and EMA.","No FDA approved drugs currently for relapsed/refractory AL Amyloidosis; CIRM grant adds non-dilutive funding to ongoing clinical program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213142,"accession_number":"0001493152-24-028595","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Immix Biopharma replaces auditor KMJ Corbin with Crowe LLP after KMJ partners join Crowe","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective July 17, 2024, Immix dismissed KMJ Corbin & Company LLP and appointed Crowe LLP as its independent registered public accounting firm.","Change follows the partners and professional staff of KMJ joining Crowe; no disagreements or reportable events in fiscal 2022 or 2023.","KMJ's audit reports for the two most recent fiscal years were unqualified and contained no adverse or modified opinions.","KMJ provided a letter agreeing with the dismissal statements, filed as Exhibit 16.1 to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232260,"accession_number":"0001493152-24-023947","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Immix Biopharma shareholders approve 3M-share increase and evergreen provision in equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing omnibus equity plan shares by 3,000,000 to 4,934,561 total.","Evergreen provision adopted: automatic annual increase of 5% of outstanding shares on Jan 1 for 10 years from 2025.","All eight director nominees elected; ratification of KMJ Corbin & Company LLP as auditor passed.","Meeting had 70.4% of shares present, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232259,"accession_number":"0001493152-24-020785","cik":1873835,"company_name":"Immix Biopharma, Inc.","ticker":"IMMX","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.","Issued 989,876 shares of common stock to former Nexcella stockholders (including third-party cash investors).","Issued 275,759 restricted stock awards and options to purchase 595,676 shares at $2.47 per share to former Nexcella equity plan participants.","Nexcella stockholders have appraisal rights under Delaware law if they perfect them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":467394129.68041235,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}